Program Information
Evaluation of CTV-To-PTV Expansion for Whole Breast Radiotherapy
B Burgdorf*, G Freedman , B Teo , University of Pennsylvania, Philadelphia, PA
Presentations
SU-F-J-132 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose:
The current standard CTV-to-PTV expansion for whole breast radiotherapy (WBRT) is 7mm, as recommended by RTOG-1005.This expansion is derived from the uncertainty due to patient positioning (±5mm) and respiratory motion (±5mm). We evaluated the expansion needed for respiratory motion uncertainty using 4DCT. After determining the appropriate expansion margins, RT plans were generated to evaluate the reduction in heart and lung dose.
Methods:
4DCT images were acquired during treatment simulation and retrospectively analyzed for 34 WBRT patients. Breast CTVs were contoured on the maximum inhale and exhale phase. Breast CTV displacement was measured in the L-R, A-P, and SUP-INF directions using rigid registration between phase images. Averaging over the 34 patients, we determined the margin due to respiratory motion. Plans were generated for 10 left-sided cases comparing the new expansion with the 7mm PTV expansion.
Results:
The results for respiratory motion uncertainty are shown in Table 1. Drawing on previous work by White et al at Princess Margaret Hospital (1) (see supporting document for reference) which studied the uncertainty due to patient positioning, we concluded that, in total, a 5mm expansion was sufficient. The results for our suggested PTV margin are shown in Table 2, combining the patient positioning results from White et al with our respiratory motion results. The planning results demonstrating the heart and lung dose differences in the 5mm CTV-to-PTV expanded plan compared to the 7mm plan are shown in Table 3.
Conclusion:
Our work evaluating the expansion needed for respiratory motion along with previous work evaluating the expansion needed for setup uncertainty shows that a CTV-to-PTV expansion of 5mm is acceptable and conservative. By reducing the PTV expansion, significant dose reduction to the heart and lung are achievable.
Contact Email: